We are a vertically integrated, clinical stage gene therapy company with four ongoing clinical programs and a broad pipeline of preclinical and research programs. We have core capabilities in viral vector design and optimization and gene therapy manufacturing, as well as a potentially transformative gene regulation technology. Led by an experienced management team, we have taken a portfolio approach by licensing, acquiring and developing technologies that give us depth across both product candidates and indications. Though initially focusing on the eye, salivary gland and central nervous system, we intend to expand our focus in the future to develop additional gene therapy treatments for patients suffering from a range of serious diseases. Source
No articles found.
CytoSorbents Corporation (NASDAQ: CTSO) is a New Jersey-based, critical care immun...
CytoSorbents Corporation (NASDAQ: CTSO) is a Ne...
Shionogi & Co., Ltd. engages in the research, development, supply, manufacture, an...
Shionogi & Co., Ltd. engages in the research, d...
Our strategy is to be known as âthe prostate cancer companyâ. We aspire to be ...
Our strategy is to be known as âthe prostate ...
Medigus is a medical device company specializing in developing minimally invasive ...
Medigus is a medical device company specializin...
InnaMed is developing a comprehensive care management platform. Our team is develo...
InnaMed is developing a comprehensive care mana...
Axogen (AXGN) is a global leader in innovative surgical solutions for peripheral n...
Axogen (AXGN) is a global leader in innovative ...
Rocket Pharmaceuticals, Inc. is an emerging, clinical-stage biotechnology company ...
Rocket Pharmaceuticals, Inc. is an emerging, cl...
Join the National Investor Network and get the latest information with your interests in mind.